Combined targeting of CML cells using tyrosine kinase and bone morphogenic protein inhibitors

ESH eLearning, Kudzai Nyamondo, 374356

Restoration of Mir-185 in combination with BCR-ABL downregulation by therapeutic delivery of siRNA with polymeric carriers sensitizes drug resistant cells to TKIs

ESH eLearning, Athena Phoa, 374355

The rate of cellular energy production of muscle cells attenuated by carnitine intracellular deficiency was proved in vivo

ESH eLearning, Pavel Burda, 374354

Synthetic lethality in CML - targeting metabolism effectively complements TKI treatment

ESH eLearning, Lukas Häselbarth, 374353

Immunology aspects of cancer

ESH eLearning, Toni Ribas, 374352

Molecular mechanisms of BCR-ABL regulation and its inhibition by allosteric and orthosteric inhibitors

ESH eLearning, Oliver Hantschel, 374351

Selected abstract:Modeling progression of CML using mutagenized patient-derived induced pluripotent stem cells (IPSCs)

ESH eLearning, Jusuf Imeri, 374350

Selected abstract:BCR-ABL1 -dependent promotion of hematopoietic stem cells (HSC) and progenitors in an inducible embryonic stem cell (ESC) model

ESH eLearning, Jerome Artus, 374348

Selected abstract: Single-cell multiomics reveals the stem and immune composition of stage progression in CML

ESH eLearning, Ya-Ching Hsieh, 374347

BCR::ABL1 Digital PCR identifies chronic phase CML patients suitable for an early TKI discontinuation attempt: a patient-level meta-analysis

ESH eLearning, Camille C.B. Kockerols, 374344

Glucose anaplerosis Is a BCR-ABL Independent Metabolic Vulnerability in CML

ESH eLearning, Kevin Rattigan, 374343

Asciminib provides durable molecular responses in patients with CML in chronic phase (CML-CP) with the T315I mutation: updated efficacy and safety data from a phase I trial

ESH eLearning, Fabian Lang, 374342

A shared molecular mechanism among blastic transformation, residual disease, and primary TKI resistance in CML - MS4A3 suppression

ESH eLearning, Helong Zhao, 374339

Welcome address

ESH eLearning, Jorge Cortes, 374338

Conference Book (PDF)

ESH eLearning, Faculty / Presenters, 374438

Panel Discussion

ESH eLearning, Faculty / Presenters, 373855

Waldenstrom Macroglobulinemia

ESH eLearning, Prashant Kapoor, 373854

AL Amyloidosis

ESH eLearning, Vaishali Sanchorawala, 373853

MGUS

ESH eLearning, Vincent Rajkumar, 373852

Panel Discussion

ESH eLearning, Faculty / Presenters, 373851

Endpoints for frontline therapy

ESH eLearning, Shaji Kumar, 373850

Strategic questions for investigator initated trials

ESH eLearning, Philippe Moreau, 373849

Control arms in regulatory trials

ESH eLearning, Graham Jackson, 373848

Discussion

ESH eLearning, Faculty / Presenters, 373847

Fiction

ESH eLearning, Mohamad Mohty, 373846

Reality

ESH eLearning, Adrian Mosquera, 373845

Where, when and how to use bi-specifics mAbs in MM?

ESH eLearning, Nizar J Bahlis, 373844

Where, when and how to use CAR- cells in MM?

ESH eLearning, Salomon Manier, 373843

Where, when and how to use ADC in MM?

ESH eLearning, Rakesh Popat, 373842

Panel Discussion

ESH eLearning, Faculty / Presenters, 373841

Current options for 3rd line of therapy

ESH eLearning, Fredrik Schjesvold, 373840

How to rescue patients after the SOC in 1st line in 2022?

ESH eLearning, Saad Z Usmani, 373839

Treatment at biochemical versus clinical relapse

ESH eLearning, Enrique Maria Ocio San Miguel, 373838

Panel Discussion

ESH eLearning, Faculty / Presenters, 373837

MRD evaluation in the peripheral blood

ESH eLearning, Noemi Puig, 373836

MRD evaluation by imaging

ESH eLearning, Elena Zamagni, 373835

MRD evauation in the bone marrow

ESH eLearning, Stefania Oliva, 373834

Panel Discussion

ESH eLearning, Faculty / Presenters, 373833

Ultra high risk : ASCT + immunotherapy ?

ESH eLearning, Martin Kaiser, 373832

Maintenance : 2 agents for all ?

ESH eLearning, Graham Jackson, 373831

Quadruplet induction for all patients ?

ESH eLearning, Cyrille Touzeau, 373830

Panel Discussion

ESH eLearning, Faculty / Presenters, 373829

How to assess frailty in 2022 ?

ESH eLearning, Gordon Cook, 373828

Quadruplet in elderly patients; is it manageable ?

ESH eLearning, Kwee Yong, 373827

VRD or DRd ?

ESH eLearning, Vincent Rajkumar, 373826

Panel Discussion

ESH eLearning, Faculty / Presenters, 373825

Imaging at diagnosis in 2022

ESH eLearning, Evangelos Terpos, 373824

Genetics and risk assessment

ESH eLearning, Jill Corre, 373823

Diagnostic criteria and initial workup

ESH eLearning, Albert Oriol, 373822

Panel Discussion

ESH eLearning, Faculty / Presenters, 373821

Clinical trials in SMM : past and future

ESH eLearning, Sagar Lonial, 373820

Definition of high-risk SMM in 2022

ESH eLearning, María-Victoria Mateos, 373819

Biology of smoldering : a different disease ?

ESH eLearning, Irene Ghobrial, 373818

Welcome address

ESH eLearning, Graham Jackson, 373817

Conference Book (PDF)

ESH eLearning, Faculty / Presenters, 374270

Genome editing to overcome T-cell exhaustion

ESH eLearning, Chiara Bonini, 371983

Panel Discussion

ESH eLearning, Faculty / Presenters, 371992

Super-resolution fluorescence imaging of plasma membrane receptors by dSTORM

ESH eLearning, Markus Sauer, 371989

Interrogating TCR & CAR function with high-end microscopy

ESH eLearning, Johannes Huppa, 371988

Panel Discussion

ESH eLearning, Faculty / Presenters, 371987

Selected brief oral communication: Joint forces - synergizing microbiome-derived metabolites and T cell engineering to combat solid tumors

ESH eLearning, Maik Luu, 371986

Decoding the mode of action of CAR-T cells using intravital imaging

ESH eLearning, Philippe Bousso, 371985

Panel Discussion

ESH eLearning, Faculty / Presenters, 371982

Selected brief oral communication: Pluripotent STEM cell-derived CAR-neutrophils for immunotherapy of SOLID tumors

ESH eLearning, Igor Slukvin, 371981

iPSC-derived CAR-T and CAR-NK

ESH eLearning, Maria Themeli, 371980

The big bang of universal immune receptors

ESH eLearning, Daniel Powell, 371978

Panel Discussion

ESH eLearning, Faculty / Presenters, 371977

Selected brief oral communication: Pharmacologically inhibiting MYCN improves L1CAM-directed CAR T cell efficacy against MYCN-amplified neuroblastoma

ESH eLearning, Laura Grunewald, 371976

Modification of GD2.car t-cells with a constitutively active IL7 receptor for the treatment of GD2 expressing malignancies

ESH eLearning, Cliona Rooney, 371974

Panel Discussion

ESH eLearning, Faculty / Presenters, 371971

Selected brief oral communication: Improving bone marrow homing and rersistence of CD33. CAR-CIK cells by overexpression of a gain-of-function variant of CXCR4 to increase efficacy in acute myeloid leukemia

ESH eLearning, Marta Biondi, 371970

Translation of new CAR-T cells into the clinic

ESH eLearning, Marcela Maus, 371969

Synthetic solutions for improving CAR-T solid tumor immunotherapy

ESH eLearning, Michael JENSEN, 371968

Engineering next-generation CAR-T cell therapy for cancer

ESH eLearning, Yvonne Chen, 371967

Panel Discussion

ESH eLearning, Faculty / Presenters, 371966

Selected brief oral communication: Pre-clinical development and characterization of a decitabine-induced regulatory HLAG+CD4+-T cell-enriched cell product against GvHD

ESH eLearning, Dionysia Kefala, 371965

Selected brief oral communication: CAR-Tregs for Systemic Lupus Erythematosus

ESH eLearning, Matteo Doglio, 372595

Optimization of TCR gene therapy and preventing tumor escape

ESH eLearning, Mirjam Heemskerk, 371963

Tackling mechanisms of immune escape to TCR therapy

ESH eLearning, Aude CHAPUIS, 371962

Panel Discussion

ESH eLearning, Faculty / Presenters, 371961

NK cells: next generation cell therapies for cancer

ESH eLearning, Evelyn Ullrich, 371959

Adoptive immunotherapy of acute leukemia by iNKT cells retargeted against CD1c

ESH eLearning, Giulia Casorati, 371957

Panel Discussion

ESH eLearning, Faculty / Presenters, 371956

Selected brief oral communication: EBAG9-silencing links cytolytic efficacy and memory formation in CD8+ T cells for improved cancer immunotherapy

ESH eLearning, Anthea Wirges, 371955

Advanced engineering of recombinant TCR expressing T-cells for adoptive immunotherapy

ESH eLearning, Dirk Busch, 371954

Engineering T lymphocytes with newly identified TCRs for the treatment of hematological and solid tumors

ESH eLearning, Eliana Ruggiero, 371953

Pooled CRISPR Knockin Screens: Reprogramming Therapeutic T Cells

ESH eLearning, Franziska Blaeschke, 371952

Panel Discussion

ESH eLearning, Faculty / Presenters, 371951

Selected brief oral communication: CSF1R blockade improves response to CAR T-cell in aggressive lymphoma

ESH eLearning, Philipp Gödel, 371950

Harnessing T memory stem cells for adoptive immunotherapy of cancer

ESH eLearning, Luca Gattinoni, 371948

CAR T cells – a road trip from the clinic back to the lab

ESH eLearning, Michael Hudecek, 371947

Welcome address

ESH eLearning, Faculty / Presenters, 371946

Conference Book (PDF)

ESH eLearning, Faculty / Presenters, 372511

Panel discussion

ESH eLearning, Faculty / Presenters, 366606

Rusfertide (PTG-300) Treatment Effectively Controls Hematocrit to Eliminate Need for Therapeutic Phlebotomy in Polycythemia Vera Patients

ESH eLearning, Marina Kremyanskaya, 366605

Targeting aberrant self-renewal in MPN

ESH eLearning, Catriona Jamieson, 366604

Targeting splicing factors

ESH eLearning, Timothy Graubert, 366603

Panel discussion

ESH eLearning, Faculty / Presenters, 366602

Initiation and progression of CALR mutant MPN

ESH eLearning, Ann Mullally, 366601

CALR mutations in the development of MPN using mouse modeling

ESH eLearning, Caroline Marty, 366600